CN Mobile Logo


Prostate Cancer

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Prostate Cancer

The 2012 change in guidelines regarding PSAtesting for prostate cancer had a different effect on testing rates depending on which physician specialty was doing the testing.

Combined use of systematic and targeted magnetic resonance-ultrasound–guided fusion biopsy was effective in diagnosing clinically significant prostate cancer.

More than 15% of men and women over the age of 65 may have received breast or prostate cancer screening not recommended by current guidelines.

A 55-year-old Hispanic male presents with a family history of gastric cancer in one sibling and prostate cancer in an older brother. CT performed in March 2015 for IMT surveillance showed a heterogeneous prostate with local invasion involving the bladder, seminal vesicles, and perirectal fat.

A three-arm trial found that one hypofractionation radiotherapy regimen was non-inferior to conventional RT for intermediate-risk prostate cancer patients.

Results from the large STAMPEDE trial suggest that the combination of zoledronic acid and celecoxib along with standard of care could improve failure-free survival in prostate cancer patients starting hormone therapy whose disease has metastasized.

A hypofractionated radiotherapy regimen was found to be noninferior to conventional fractionation for low-risk prostate cancer patients in a new randomized phase III trial.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.